| Powder: | Yes |
|---|---|
| Customized: | Non-Customized |
| Certification: | GMP, HSE, ISO 9001, USP, BP |
| Suitable for: | Elderly, Children, Adult |
| State: | Powder |
| Purity: | >99% |
| Samples: |
|---|
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier 
| Product Name | Supply 99% Raw Material Bosutinib Pharmaceutical Powder CAS 380843-75-4 Bosutinib |
| Appearance | White powder |
| Molecular formula | C26H29Cl2N5O3 |
| Molecular weight | 530.45 |
| Keywords | Powder Bosutinib,Price Bosutinib; Pure Bosutinib |
| Shelf Life | 24 months when properly stored |
| Storage | Keep in a cool, dry, dark location |
What is Bosutinib?
Bosutinib is a synthetic quinolone derivative and dual kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity. Unlike imatinib, bosutinib inhibits the autophosphorylation of both Abl and Src kinases, resulting in inhibition of cell growth and apoptosis. Because of the dual mechanism of action, this agent may have activity in resistant CML disease, other myeloid malignancies and solid tumors. Abl kinase is upregulated in the presence of the abnormal Bcr-abl fusion protein which is commonly associated with chronic myeloid leukemia (CML). Overexpression of specific Src kinases is also associated with the imatinib-resistant CML phenotype.
Function of Bosutinib?
Bosutinib is a tyrosinase inhibitor indicated for the treatment of chronic myeloid leukemia in patients with chronic, accelerated or blast phase Ph+ who have not responded to prior therapy. Animal studies have shown that bosutinib can reduce tumors and inhibit the growth of myeloid tumors that express the Bcr-Abl gene and are resistant to imatinib.
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}